Business   

Roche's India plans

By Our Staff Correspondent

MUMBAI NOV. 4. Roche Scientific Company (India) Ltd. (RSPICL), a wholly owned subsidiary of F. Hoffman - La Roche (FHLR), has announced its plans in India starting with the appointment of Taksal Pharma Pvt. Ltd. as the new importer and distributor of FHLR in India.

After a contractual relationship of ten years with Nicholas Piramal (NPIL), FHLR decided to end the Frame Cooperation Agreement this month. This means that NPIL would not have any access to new Roche Pharma products for distribution.

FHLR plans to invest over 10 million Swiss Francs in India in the next fiscal year. It has also announced a reduction in prices of its existing therapies.

Also, for the first time, Roche is looking at introducing therapies in the areas of dermatology and osteoporosis in India. Therapies like anti-CMV and treatment of bone metastasis are in the pipeline for India in the coming year. The company will be launching CRC (colorectal and renal cancer) drugs. Roche is also introducing the EAP in India where a molecule tried internationally is available for treating Indian patients much before the International approval.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Unified regime offers level playing field — Crisil
• Indraprastha Gas' offer for sale
• Impressive show by emerging IT States
• Sensex continues to rise
• Roche's India plans
• HPCL to expand Mumbai, Vizag refinery capacity
• Rupee ends lower
• Canara Bank launches two retail products
• Dabur pays 60 p.c. interim
• Exchange rates
• Stock Market Index
• Bullion rates

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu